TORONTO, ONTARIO--(Marketwired - Feb. 21, 2017) - Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) a portfolio based biotechnology company, intends to complete a non-brokered private placement offering of up to 1,000,000 common shares priced at $0.40 per common share (the "Common Shares") for gross proceeds of up to $400,000 (the "Offering").
Arch Biopartners Appoints Patrick Vink to Board of Directors
TORONTO, CANADA--(Marketwired - Dec. 12, 2016) - Arch Biopartners, Inc., (TSX VENTURE:ACH) (OTCBB:FOIFF) (Arch or the Company) is pleased to announce that Dr. Patrick Vink has joined its Board of Directors effective December 12th, 2016.
Arch Biopartners Collaborates With Team at Cincinnati Veterans Affairs Medical Center to Prepare Phase I and II Human Trial Protocol and Application for AB569
TORONTO, ONTARIO--(Marketwired - Oct. 27, 2016) - Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) today announced it has agreed to sponsor Dr. Ralph Panos and his clinical trial team at the Cincinnati Veterans Affairs Medical Center (CVAMC) to prepare a phase I and phase II human trial protocol and an application to conduct investigator initiated trials evaluating the safety and efficacy of AB569.